Literature DB >> 28053763

Diagnostic challenges in vacuolar myelopathy: a didactic case report.

Florian Ernst1, Fritz Klausner2, Waltraud Kleindienst1, Heinrich Bartsch3, Ninon Taylor4, Eugen Trinka1.   

Abstract

INTRODUCTION: Because of the diagnostic complexity and potential pitfalls in interpreting test results, HIV-vacuolar myelopathy (HIVM) is far more often diagnosed postmortem than in vivo. In the era of highly active antiretroviral therapy (HAART), the topic of neuro-AIDS has become increasingly important. This case report covers some of the diagnostic problems encountered in vacuolar myelopathy based on magnetic resonance imaging (MRI) fiber-tracking pictures of the spine in a patient with HIVM, including a 1-year follow-up. CASE
PRESENTATION: A 49-year-old man felt progressive weakness, and difficulties while walking, and he suffered from incomplete voiding. A week before admission, follicles appeared on the right side of his neck and shoulder. His medical history included a chronic HIV infection treated with HAART and a B-cell lymphoma in complete remission after chemotherapy. The initial exam revealed thoracic hyposensitivity level distal to dermatome Th9, spastic paraparesis of the lower limbs and herpes zoster infection in dermatome C3/C4. A lesion of the thoracic myelon could be ruled out in the MRI scan, chemotherapy-induced polyneuropathy was stable, and no acute opportunistic infection of the CNS was found. HIV load in cerebrospinal fluid (CSF) was markedly elevated. An HIV-associated vacuolar myelopathy was diagnosed, revealing the HIV itself as etiology. DISCUSSION: A negative or unspecific MRI scan excludes possible other causes, but by no means rules out HIV-related myelopathy. Furthermore, peripheral and central viral load should always be assessed to avoid missing a possible 'CSF HIV-escape'.

Entities:  

Keywords:  Central nervous system infections; Disability; Infection; Neurological manifestations; Spinal cord

Year:  2016        PMID: 28053763      PMCID: PMC5129393          DOI: 10.1038/scsandc.2016.20

Source DB:  PubMed          Journal:  Spinal Cord Ser Cases        ISSN: 2058-6124


  5 in total

1.  Vacuolar myelopathy: a case report of functional, clinical, and radiological improvement after highly active antiretroviral therapy.

Authors:  Maresce Bizaare; Halima Dawood; Anand Moodley
Journal:  Int J Infect Dis       Date:  2007-12-21       Impact factor: 3.623

2.  MR findings in AIDS-associated myelopathy.

Authors:  J Chong; A Di Rocco; M Tagliati; F Danisi; D M Simpson; S W Atlas
Journal:  AJNR Am J Neuroradiol       Date:  1999-09       Impact factor: 3.825

3.  Clinicopathologic correlations of HIV-1-associated vacuolar myelopathy: an autopsy-based case-control study.

Authors:  G J Dal Pan; J D Glass; J C McArthur
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

4.  Infectious myelopathies.

Authors:  Tracey A Cho; Henrikas Vaitkevicius
Journal:  Continuum (Minneap Minn)       Date:  2012-12

Review 5.  Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities.

Authors:  Yok-Lam Kwong; Dominic Y M Yeung; Joyce C W Chan
Journal:  Ann Hematol       Date:  2008-12-03       Impact factor: 3.673

  5 in total
  2 in total

1.  HIV-Associated Vacuolar Encephalomyelopathy.

Authors:  Gregory R Madden; Molly E Fleece; Akriti Gupta; M Beatriz S Lopes; Scott K Heysell; Christopher J Arnold; Brian Wispelwey
Journal:  Open Forum Infect Dis       Date:  2019-10-01       Impact factor: 3.835

2.  Human immunodeficiency virus-associated vacuolar encephalomyelopathy with granulomatous-lymphocytic interstitial lung disease improved after antiretroviral therapy: a case report.

Authors:  Kazumasa Akagi; Kazuko Yamamoto; Asuka Umemura; Shotaro Ide; Tatsuro Hirayama; Takahiro Takazono; Yoshifumi Imamura; Taiga Miyazaki; Noriho Sakamoto; Hirokazu Shiraishi; Hideaki Takahata; Yoshiaki Zaizen; Junya Fukuoka; Minoru Morikawa; Kazuto Ashizawa; Katsuji Teruya; Koichi Izumikawa; Hiroshi Mukae
Journal:  AIDS Res Ther       Date:  2020-07-09       Impact factor: 2.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.